Want to see GB:MET full AI Analyst Report?
Top Page
Microsaic Systems
(LSE:MET)
Select Model
Select Model
Rating:43Neutral
Price Target:
0.65 p
▼(-7.00% Downside)
Action:Reiterated
Date:07/10/26
The score is primarily held down by weak financial performance: the business remains loss-making with ongoing negative cash flow despite improved 2025 revenue and gross margin. Technical indicators are mixed and do not show strong momentum, and valuation support is limited because earnings are negative and no dividend yield is available.
Positive Factors
Revenue and Gross Margin Recovery
The sharp 2025 revenue rebound and return to positive gross margin indicate renewed demand for the company’s analytical instrumentation. If maintained, improved commercial traction could provide greater operating leverage and create a foundation for scaling the business over the next several quarters.
Negative Factors
Persistent Operating Losses
The return to positive gross margin has not translated into sustainable profitability, showing that operating costs still materially exceed revenue. Continued losses weaken internal funding capacity and mean the company has yet to demonstrate a durable earnings model despite the latest sales recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Gross Margin Recovery
The sharp 2025 revenue rebound and return to positive gross margin indicate renewed demand for the company’s analytical instrumentation. If maintained, improved commercial traction could provide greater operating leverage and create a foundation for scaling the business over the next several quarters.
Read all positive factors
Microsaic Systems (MET) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.99M
Dividend YieldN/A
Average Volume (3M)1.38M
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees5
SectorTechnology
Sector Strength88
IndustryMedical - Specialties
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding443,239,500
10 Day Avg. Volume1,010,249
30 Day Avg. Volume1,378,174
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.61
Price to Sales (P/S)1.38
P/FCF Ratio-2.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Microsaic Systems Business Overview & Revenue Model
Company Description
Metir Plc engages in the research, development, and commercialization of scientific instruments. It also develops mass spectrometry instruments for the analysis of gaseous, liquid, and solid samples. The company was founded in 2001 and is headquar...
How the Company Makes Money
Microsaic Systems makes money primarily by selling analytical instrumentation and associated solutions. Its revenue model is centered on: (1) Product sales: selling mass spectrometers and integrated/related hardware used for chemical detection and...
Microsaic Systems Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Jun 2025 | Jun 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.44M | 232.00K | 492.00K | 1.57M | 906.88K |
| Gross Profit | 488.00K | -125.00K | 13.00K | 949.37K | 380.65K |
| EBITDA | -799.00K | -1.76M | -2.31M | -2.25M | -3.19M |
| Net Income | -867.00K | -1.81M | -2.60M | -2.29M | -3.13M |
Balance Sheet | |||||
| Total Assets | 2.01M | 1.40M | 713.00K | 3.13M | 5.16M |
| Cash, Cash Equivalents and Short-Term Investments | 1.06M | 188.00K | 173.00K | 1.24M | 3.46M |
| Total Debt | 5.00K | 19.00K | 21.00K | 56.25K | 127.34K |
| Total Liabilities | 778.00K | 1.22M | 569.00K | 408.08K | 581.92K |
| Stockholders Equity | 1.24M | 184.00K | 144.00K | 2.72M | 4.57M |
Cash Flow | |||||
| Free Cash Flow | -801.00K | -1.85M | -1.07M | -2.34M | -1.94M |
| Operating Cash Flow | -767.00K | -1.66M | -1.06M | -2.13M | -1.60M |
| Investing Cash Flow | -34.00K | -175.00K | 48.00K | -211.95K | -334.22K |
| Financing Cash Flow | 1.67M | 1.84M | -59.00K | 121.89K | 5.01M |
Microsaic Systems Technical Analysis
Negative
0.70
Price Trends
0.73
Negative
0.71
Negative
0.74
Negative
Market Momentum
-0.01
Negative
36.72
Neutral
56.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:MET, the sentiment is Negative. The current price of 0.7 is above the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.73, and below the 200-day MA of 0.74, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 36.72 is Neutral, neither overbought nor oversold. The STOCH value of 56.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:MET.
Microsaic Systems Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
56 Neutral | £5.92M | 21.33 | 4.92% | ― | ― | ― | |
45 Neutral | £3.89M | -8.96 | 33.06% | ― | -100.00% | -38.78% | |
44 Neutral | £1.86M | -2.60 | -28.54% | ― | -45.74% | -33.33% | |
43 Neutral | £2.99M | -1.93 | -122.11% | ― | ― | ― | |
30 Underperform | £1.89M | -0.34 | -586.74% | ― | 2.82% | 70.83% |
* Technology Sector Average
GB:MET
Microsaic Systems
0.68
-0.43
-38.64%
GB:TIDE
Crimson Tide
90.00
27.50
44.00%
GB:SYME
Supply@ME
0.01
0.00
0.00%
GB:CTAI
Catenae Innovation Plc
0.13
-0.19
-59.38%
GB:RDT
Rosslyn Data Technologies
1.60
-2.30
-58.97%
GB:AIQ
AIQ Limited
6.00
0.00
0.00%
Microsaic Systems Corporate Events
Business Operations and StrategyShareholder Meetings
Metir Wins Strong Shareholder Backing as All AGM Resolutions Pass
Positive
Aug 6, 2026
Metir plc reported that all resolutions at its 6 August 2026 Annual General Meeting were passed by poll, including approval of the 2025 Annual Report and Accounts and the re-election of directors Chris Potts, Nigel Burton and Robert Moore. Shareho...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Metir accelerates water monitoring rollout and prepares QuickChek SRB relaunch
Positive
Aug 4, 2026
Metir plc reported growing commercial momentum for its Microtox LX water toxicity platform, with rising production enabling sales from stock, expanded trials and 19 systems sold so far in 2026. The board expects the enlarging installed base to dri...
Business Operations and Strategy
Metir Wins Long-Term Backing for Qatar Water Toxicity Monitoring Project
Positive
Jul 23, 2026
Metir has secured formal confirmation of long-term support for its Continuous Toxicity Monitoring project in Qatar, where its Modern Water division is the sole supplier of the CTM technology. Following a stakeholder meeting, a project confirmation...
Business Operations and Strategy
Metir strikes GCC-focused water monitoring and purification partnership with Portsmouth Aviation
Positive
Jul 17, 2026
Metir plc has signed a strategic Memorandum of Understanding with Portsmouth Aviation’s Paqua division to explore integrated water treatment and biological monitoring solutions. The partnership combines PaquaVida’s mobile water purific...
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Metir plc Publishes 2025 Annual Report and Sets Date for AGM
Neutral
Jul 8, 2026
Metir plc has released its Notice of Annual General Meeting, confirming that the document, along with the 2025 Annual Report and Accounts and proxy form, is now available to shareholders and on the company’s website. The AGM will take place ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Metir plc posts fivefold revenue jump as PFAS and pathogen platforms gain traction
Positive
Jul 7, 2026
Metir plc reported a transformative 2025, shifting from restructuring to strong commercial delivery in water and environmental monitoring. Revenue surged 521% to £1.44m on robust Microtox LX sales, growing reagent volumes and income recogniti...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Metir Faces AIM Share Suspension After Delay to FY25 Annual Report
Negative
Jun 30, 2026
Metir plc, a leading global supplier of fast-response mobile and point-of-use water and environmental monitoring technologies, operates through its Modern Water division for Microtox® toxicity testing and Microsaic Systems for mobile PFAS det...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.